Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines

References

• Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28. doi:10.1016/S0140-6736(14)61403-3. PMID:25319501.
   PubMed Web of Science ®Google Scholar
• Maude, SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17. doi:10.1056/NEJMoa1407222. PMID:25317870.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014. 6(224):224ra25. doi:10.1126/scitranslmed.3008226. PMID:24553386.
   PubMed Web of Science ®Google Scholar
• Schubert, ML, Hückelhoven A, Hoffmann JM, Schmitt A, Wuchter P, Sellner L, Hofmann S, Ho AD, Dreger P, Schmitt M. Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation. Hum Gene Ther. 2016;10:758–771. doi:10.1089/hum.2016.097. PMID:27479233.
   PubMed Web of Science ®Google Scholar
• Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126(8):983–92. doi:10.1182/blood-2015-02-629527. PMID:26056165.
   PubMed Web of Science ®Google Scholar
• Pui CH, Behm, FG, Crist, WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood. 1993;82(2):343–62. PMID:8329694.
   PubMed Web of Science ®Google Scholar
• Campana D, van Dongen JJ, Mehta A, Coustan-Smith E, Wolvers-Tettero IL, Ganeshaguru K, Janossy G. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood. 1991;77(7):1546–54. PMID:1826223.
   PubMed Web of Science ®Google Scholar
• Osman N, Ley, SC, Crumpton, MJ. Evidence for an association between the T cell receptor/CD3 antigen complex and the CD5 antigen in human T lymphocytes. Eur J Immunol. 1992;22(11):2995–3000. doi:10.1002/eji.1830221135. PMID:1385158.
   PubMed Web of Science ®Google Scholar
• Berland R, Wortis, HH. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol. 2002;20:253–300. doi:10.1146/annurev.immunol.20.100301.064833. PMID:11861604.
   PubMed Web of Science ®Google Scholar
• Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J Exp Med. 1998;188(12):2301–11. doi:10.1084/jem.188.12.2301. PMID:9858516.
   PubMed Web of Science ®Google Scholar
• Sigal LH. Basic science for the clinician 54: CD5. J Clin Rheumatol, 2012;18(2):83–8. doi:10.1097/RHU.0b013e318247bc64. PMID:22334268.
   PubMed Web of Science ®Google Scholar
• Bikah G, Carey J, Ciallella JR, Tarakhovsky A, Bondada S. CD5-Mediated Negative Regulation of Antigen Receptor-Induced Growth Signals in B-1 B Cells. Science. 1996;274(5294):1906–1909. doi:10.1126/science.274.5294.1906. PMID:8943203.
   PubMed Web of Science ®Google Scholar
• Dalloul A. CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun Rev. 2009;8(4):349–53. doi:10.1016/j.autrev.2008.11.007. PMID:19041428.
   PubMed Web of Science ®Google Scholar
• Bertram JH, Gill PS, Levine AM, Boquiren D, Hoffman FM, Meyer P, Mitchell MS. Monoclonal antibody T101 in T cell malignancies: a clinical, pharmacokinetic, and immunologic correlation. Blood. 1986;68(3):752–61. PMID:3488778.
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Drajesk J, Fishwild D, Scannon P, Byers V. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood. 1991;78(5):1173–82. PMID:1878584.
   PubMed Web of Science ®Google Scholar
• Chen KH, Wada M, Pinz KG, Liu H, Lin KW, Jares A, Firor AE, Shuai X, Salman H, Golightly M. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia. 2017;31(10):2151–2160. doi:10.1038/leu.2017.8. PMID:28074066.
   PubMed Web of Science ®Google Scholar
• Wiedenheft B, Sternberg, SH, Doudna, JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482(7385):331–8. doi:10.1038/nature10886. PMID:22337052.
   PubMed Web of Science ®Google Scholar
• Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–21. doi:10.1126/science.1225829. PMID:22745249.
   PubMed Web of Science ®Google Scholar
• Mojica FJ, Díez-Villaseñor C, García-Martínez J, Almendros C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology. 2009;155(Pt 3):733–40. PMID:19246744.
   PubMed Web of Science ®Google Scholar
• Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709–12. doi:10.1126/science.1138140. PMID:17379808.
   PubMed Web of Science ®Google Scholar
• Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ, Root DE. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol. 2014;32(12):1262–7. doi:10.1038/nbt.3026. PMID:25184501.
   PubMed Web of Science ®Google Scholar
• Cong L, Zhang, F. Genome engineering using CRISPR-Cas9 system. Methods Mol Biol. 2015;1239:197–217. doi:10.1007/978-1-4939-1862-1_10. PMID:25408407.
   PubMedGoogle Scholar
• Kaya H, Mikami M, Endo A, Endo M, Toki S. Highly specific targeted mutagenesis in plants using Staphylococcus aureus Cas9. Sci Rep. 2016;6:26871. doi:10.1038/srep26871. PMID:27226350.
   PubMed Web of Science ®Google Scholar
• Moot R, Raikar SS, Fleischer L, Querrey M, Tylawsky DE, Nakahara H, Doering CB, Spencer HT. Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors. Mol Ther Oncolytics. 2016;3:16026. doi:10.1038/mto.2016.26. PMID:27933313.
   PubMed Web of Science ®Google Scholar
• Herrin BR, Cooper, MD. Alternative adaptive immunity in jawless vertebrates. J Immunol. 2010;185(3):1367–74. doi:10.4049/jimmunol.0903128. PMID:20660361.
   PubMed Web of Science ®Google Scholar
• Mariuzza RA, Velikovsky CA, Deng L, Xu G, Pancer Z. Structural insights into the evolution of the adaptive immune system: the variable lymphocyte receptors of jawless vertebrates. Biol Chem. 2010;391(7):753–60. doi:10.1515/bc.2010.091. PMID:20482318.
   PubMed Web of Science ®Google Scholar
• Boehm T, McCurley N, Sutoh Y, Schorpp M, Kasahara M, Cooper MD. VLR-based adaptive immunity. Annu Rev Immunol. 2012;30:203–20. doi:10.1146/annurev-immunol-020711-075038. PMID:22224775.
   PubMed Web of Science ®Google Scholar
• Kasahara M, Sutoh Y. Two forms of adaptive immunity in vertebrates: similarities and differences. Adv Immunol. 2014;122:59–90. doi:10.1016/B978-0-12-800267-4.00002-X. PMID:24507155.
   PubMed Web of Science ®Google Scholar
• Yu C, Ali S, St-Germain J, Liu Y, Yu X, Jaye DL, Moran MF, Cooper MD, Ehrhardt GR. Purification and identification of cell surface antigens using lamprey monoclonal antibodies. J Immunol Methods. 2012;386(1-2):43–9. doi:10.1016/j.jim.2012.08.016. PMID:22964555.
   PubMed Web of Science ®Google Scholar
• Kirchdoerfer RN, Herrin BR, Han BW, Turnbough CL Jr., Cooper MD, Wilson IA. Variable lymphocyte receptor recognition of the immunodominant glycoprotein of Bacillus anthracis spores. Structure. 2012;20(3):479–86. doi:10.1016/j.str.2012.01.009. PMID:22405006.
   PubMed Web of Science ®Google Scholar
• Studnicka GM, Soares S, Better M, Williams RE, Nadell R, Horwitz AH. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng. 1994;7(6):805–14. doi:10.1093/protein/7.6.805. PMID:7937712.
   PubMedGoogle Scholar
• Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D, Warren F, Keck P, Oppermann H. Medical applications of single-chain antibodies. Int Rev Immunol. 1993;10(2-3):195–217. doi:10.3109/08830189309061696. PMID:8360586.
   PubMedGoogle Scholar
• Gong JH, Maki, G, Klingemann, HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652–8. PMID:8152260.
   PubMed Web of Science ®Google Scholar
• Lee-MacAry AE, Ross EL, Davies D, Laylor R, Honeychurch J, Glennie MJ, Snary D, Wilkinson RW. Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide. J Immunol Methods. 2001;252(1-2):83–92. doi:10.1016/S0022-1759(01)00336-2. PMID:11334968.
   PubMed Web of Science ®Google Scholar
• Renaudineau Y, Hillion S, Saraux A, Mageed RA, Youinou P. An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes. Blood. 2005;106(8):2781–9. doi:10.1182/blood-2005-02-0597. PMID:15998834.
   PubMed Web of Science ®Google Scholar
• Cradick TJ, Qiu P, Lee CM, Fine EJ, Bao G. COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites. Mol Ther Nucleic Acids 2014;3:e214. doi:10.1038/mtna.2014.64. PMID:25462530.
   PubMedGoogle Scholar
• Brinkman, EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42(22):e168. doi:10.1093/nar/gku936. PMID:25300484.
   PubMed Web of Science ®Google Scholar
• Henze, G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, Riehm H. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood. 1991;78(5):1166–72. PMID:1878583.
   PubMed Web of Science ®Google Scholar
• Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hählen K, Göbel U, Klingebiel T, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol. 2005;23(31):7942–50. doi:10.1200/JCO.2005.01.1031. PMID:16258094.
   PubMed Web of Science ®Google Scholar
• Reismuller B, Peters C, Dworzak MN, Pötschger U, Urban C, Meister B, Schmitt K, Dieckmann K, Gadner H, Attarbaschi A, et al. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group. J Pediatr Hematol Oncol. 2013;35(5):e200–4. doi:10.1097/MPH.0b013e318290c3d6. PMID:23652878.
   PubMed Web of Science ®Google Scholar
• Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, et al. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(12):2154–9. doi:10.1016/j.bbmt.2015.08.023. PMID:26327632.
   PubMed Web of Science ®Google Scholar
• Bakr M, Rasheed W, Mohamed SY, Al-Mohareb F, Chaudhri N, Al-Sharif F, Al-Zahrani H, Al-Dawsari G, Saleh AJ, Nassar A, et al. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012;18(12):1897–904. doi:10.1016/j.bbmt.2012.07.011. PMID:22824185.
   PubMed Web of Science ®Google Scholar
• Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol. 2008;26(24):3971–8. doi:10.1200/JCO.2008.16.1414. PMID:18711187.
   PubMed Web of Science ®Google Scholar
• Laurent G, Pris J, Farcet JP, Carayon P, Blythman H, Casellas P, Poncelet P, Jansen FK. Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood. 1986;67(6):1680–7. PMID:3085747.
   PubMed Web of Science ®Google Scholar
• Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994;13(5):571–5. PMID:7519937.
   PubMed Web of Science ®Google Scholar
• Byers VS, Henslee PJ, Kernan NA, Blazar BR, Gingrich R, Phillips GL, LeMaistre CF, Gilliland G, Antin JH, Martin P. Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood. 1990;75(7):1426–32. PMID:2180494.
   PubMed Web of Science ®Google Scholar
• Tarakhovsky A, Kanner SB, Hombach J, Ledbetter JA, Müller W, Killeen N, Rajewsky K. A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science. 1995;269(5223):535–537. doi:10.1126/science.7542801. PMID:7542801.
   PubMed Web of Science ®Google Scholar
• Krammer PH, Arnold, R, Lavrik, IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007;7(7):532–42. doi:10.1038/nri2115. PMID:17589543.
   PubMed Web of Science ®Google Scholar
• Hermanson DL, Kaufman, DS. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol. 2015;6:195. doi:10.3389/fimmu.2015.00195. PMID:25972867.
   PubMed Web of Science ®Google Scholar
• Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, Grez M, Kloess S, Arseniev L, Koehl U. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015;6:21. doi:10.3389/fphar.2015.00021. PMID:25729364.
   PubMed Web of Science ®Google Scholar
• Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology. 2014;3:e28147. doi:10.4161/onci.28147. PMID:25340009.
   PubMed Web of Science ®Google Scholar
• Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T. NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother. 2015. PMID:26559813.
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28(4):917–27. doi:10.1038/leu.2013.279. PMID:24067492.
   PubMed Web of Science ®Google Scholar
• Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, Ottmann OG, Tonn T. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 2016;20(7):1287–94. doi:10.1111/jcmm.12810. PMID:27008316.
   PubMed Web of Science ®Google Scholar
• Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19(2):235–249. doi:10.1016/j.jcyt.2016.10.009. PMID:27887866.
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology. 2013;2(10):e26527. doi:10.4161/onci.26527. PMID:24404423.
   PubMed Web of Science ®Google Scholar
• Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23(2):330–8. doi:10.1038/mt.2014.219. PMID:25373520.
   PubMed Web of Science ®Google Scholar
• Chu Y, Hochberg J, Yahr A, Ayello J, van de Ven C, Barth M, Czuczman M, Cairo MS. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice. Cancer Immunol Res. 2015;3(4):333–44. doi:10.1158/2326-6066.CIR-14-0114. PMID:25492700.
   PubMed Web of Science ®Google Scholar
• Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med. 2012;16(3):569–81. doi:10.1111/j.1582-4934.2011.01343.x. PMID:21595822.
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, Zeng T, Huang H, Zhang X, Sun W. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014;8(2): p. 297–310. doi:10.1016/j.molonc.2013.12.001. PMID:24388357.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Coustan-Smith E, Kamiya T, Campana D. Expanded and armed natural killer cells for cancer treatment. Cytotherapy. 2016;18(11):1422–1434. doi:10.1016/j.jcyt.2016.06.013. PMID:27497701.
   PubMed Web of Science ®Google Scholar
• Li L, Allen C, Shivakumar R, Peshwa MV. Large volume flow electroporation of mRNA: clinical scale process. Methods Mol Biol 2013;969:127–38. doi:10.1007/978-1-62703-260-5_9. PMID:23296932.
   PubMedGoogle Scholar
• Chu Y, Flower, A, Cairo, MS. Modification of Expanded NK Cells with Chimeric Antigen Receptor mRNA for Adoptive Cellular Therapy. Methods Mol Biol. 2016;1441:215–30. doi:10.1007/978-1-4939-3684-7_18. PMID:27177669.
   PubMedGoogle Scholar
• Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Snijders AP, Dickman MJ, Makarova KS, Koonin EV, van der Oost J. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. 2008;321(5891):960–4. doi:10.1126/science.1159689. PMID:18703739.
   PubMed Web of Science ®Google Scholar
• Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281–308. doi:10.1038/nprot.2013.143. PMID:24157548.
   PubMed Web of Science ®Google Scholar
• Anders C, Niewoehner O, Duerst A, Jinek M. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature. 2014;513(7519):569–73. doi:10.1038/nature13579. PMID:25079318.
   PubMed Web of Science ®Google Scholar
• Cyranoski D. First trial of CRISPR in people. Nature. 2016;535(7613):476–477. doi:10.1038/nature.2016.20302. PMID:27466105.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004;173(12):7647–53. doi:10.4049/jimmunol.173.12.7647. PMID:15585893.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach, AA, Abken, H. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack. Gene Ther. 2011;18(1):62–72. doi:10.1038/gt.2010.127. PMID:20944680.
   PubMed Web of Science ®Google Scholar